GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
Pozen is counting on safety data from two GSK Phase IIIb trials completed after the migraine therapy’s filing to satisfy FDA’s “approvable” letter.